Page last updated: 2024-08-26

fulvestrant and carbostyril

fulvestrant has been researched along with carbostyril in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Christos, PJ; Hershman, DL; Hoschander, S; Li, T; O'Brien, K; Sparano, JA; Vahdat, LT; Wright, JJ	1
Barnfather, P; Barrett-Lee, P; Bramble, P; Christensen, J; Hayes, E; Hiscox, S; Nicholson, RI	1
Dolcet, X; Domingo, M; Dosil, MA; Eritja, N; Llombart-Cussac, A; Matias-Guiu, X; Mirantes, C; Santacana, M; Valls, J	1
André, F; Barrios, CH; Blackwell, K; Bonnefoi, H; Campone, M; Cortes, J; Denduluri, N; Deudon, S; Kahan, Z; Musolino, A; Neven, P; Shi, MM; Soliman, H; Squires, M; Zhang, Y	1

Trials

2 trial(s) available for fulvestrant and carbostyril

Article	Year
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Farnesyltranstransferase; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome	2009
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR Breast cancer research : BCR, 2017, 02-10, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Survival Analysis; Treatment Outcome	2017

Article

Year

Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.

Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:4

Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Farnesyltranstransferase; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome

2009

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR

Breast cancer research : BCR, 2017, 02-10, Volume: 19, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Survival Analysis; Treatment Outcome

2017

Other Studies

2 other study(ies) available for fulvestrant and carbostyril

Article	Year
Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast cancer research and treatment, 2011, Volume: 125, Issue:3 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Endocrine System; Enzyme Inhibitors; Estradiol; Focal Adhesion Protein-Tyrosine Kinases; Fulvestrant; Humans; Inhibitory Concentration 50; Phenotype; Quinolones; Sulfones; Tamoxifen	2011
Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells. Molecular cancer therapeutics, 2014, Volume: 13, Issue:4 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, SCID; Mutation; Neoplasms, Experimental; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Xenograft Model Antitumor Assays	2014

Article

Year

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.

Breast cancer research and treatment, 2011, Volume: 125, Issue:3

Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Endocrine System; Enzyme Inhibitors; Estradiol; Focal Adhesion Protein-Tyrosine Kinases; Fulvestrant; Humans; Inhibitory Concentration 50; Phenotype; Quinolones; Sulfones; Tamoxifen

2011

Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.

Molecular cancer therapeutics, 2014, Volume: 13, Issue:4

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, SCID; Mutation; Neoplasms, Experimental; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Xenograft Model Antitumor Assays

2014